https://www.onclive.com/view/litespark-022-pro-data-further-support-adjuvant-belzutifan-plus-pembrolizumab-in-ccrcc2026-11-11T22:30:06.784Z2026-11-11T22:30:06.784Z https://www.onclive.com/view/first-line-niraparib-maintenance-yields-longer-pfs-in-hrd-positive-vs-hrd-negative-optimally2026-11-11T19:00:00Z2026-11-11T19:00:00Z https://www.onclive.com/view/sonrotoclax-based-regimens-elicit-responses-in-relapsed-refractory-mcl2026-11-11T17:47:30.052Z2026-11-11T17:47:30.052Z https://www.onclive.com/view/interpreting-her2-results-on-reports-and-why-the-tyrosine-kinase-domain-matters2026-11-11T13:15:00Z2026-11-11T13:15:00Z https://www.onclive.com/view/classification-and-grading-of-neuroendocrine-tumors2026-11-11T13:05:00Z2026-11-11T13:05:00Z https://www.onclive.com/view/local-therapy-for-oligoprogression-and-consolidation-in-egfr-mutant-nsclc2026-11-11T13:05:00.000Z2026-11-11T13:05:00Z https://www.onclive.com/view/retesting-strategies-and-psma-pet-selection-in-advanced-prostate-cancer2026-11-11T13:05:00Z2026-11-11T13:05:00Z https://www.onclive.com/view/infection-prevention-and-dosing-strategies-for-bcma-directed-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-11-11T13:05:00Z2026-11-11T13:05:00Z https://www.onclive.com/view/treatment-selection-after-immunotherapy-in-squamous-nsclc2026-11-11T13:05:00Z2026-11-11T13:05:00Z https://www.onclive.com/view/setting-expectations-with-trial-outcomes2026-11-11T13:05:00Z2026-11-11T13:05:00Z https://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-october-20262026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/introducing-the-landscape-of-her2-mutant-non-small-cell-lung-cancer2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/timing-and-choosing-tissue-vs-ctdna-testing-in-metastatic-prostate-cancer2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/closing-perspectives-individualized-care-and-the-path-beyond-steroids2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/rasolute-302-design-and-study-populations2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/arcotatug-tavatecan-ibi343-tak-921-versus-treatment-of-physician-s-choice-tpc-in-previously-treated-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-g-geja-first-interim-analysis-of-the-randomized-open-label-phase-3-g-hope-001-study2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/treatment-options-for-squamous-nsclc-after-immunotherapy2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/accessing-multidisciplinary-net-care-from-the-community2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/evaluating-progression-on-first-line-osimertinib-and-the-role-of-rebiopsy2026-11-11T13:00:00.000Z2026-11-11T13:00:00Z https://www.onclive.com/view/supportive-care-and-toxicity-management-in-relapsed-refractory-multiple-myeloma2026-11-11T13:00:00Z2026-11-11T13:00:00Z https://www.onclive.com/view/dr-nunnery-on-chemo-de-escalation-ovarian-function-suppression-and-toxicity-management-in-breast-cancer2026-11-11T02:00:00Z2026-11-11T02:00:00Z https://www.onclive.com/view/dr-natsuhara-on-treatment-advances-and-research-considerations-in-tnbc2026-11-11T01:30:00Z2026-11-11T01:30:00Z https://www.onclive.com/view/genomic-testing-toxicity-and-sequencing-shape-treatment-decisions-in-advanced-prostate-cancer2026-11-10T23:02:44.754Z2026-11-10T23:02:44.754Z https://www.onclive.com/view/natalee-6-year-os-data-and-novel-adcs-in-breast-cancer-take-center-stage-at-esmo-20262026-11-10T22:10:02.301Z2026-11-10T22:10:02.301Z https://www.onclive.com/view/mo-rez-responses-span-b7-h4-expression-levels-in-platinum-resistant-ovarian-cancer-in-behold-12026-11-10T19:00:00Z2026-11-10T19:00:00Z https://www.onclive.com/view/fda-approves-pimicotinib-for-symptomatic-tgct2026-11-10T17:48:43.676Z2026-11-10T17:48:43.676Z https://www.onclive.com/view/fda-approves-companion-diagnostic-for-pembrolizumab-in-msi-h-solid-tumors2026-11-10T16:30:37.124Z2026-11-10T16:30:37.124Z https://www.onclive.com/view/prizlon-cel-nets-fda-rmat-and-fast-track-designations-in-r-r-lbcl2026-11-10T16:24:08.294Z2026-11-10T16:24:08.294Z https://www.onclive.com/view/longer-follow-up-of-behold-1-shows-durable-responses-with-mo-rez-in-platinum-resistant-ovarian2026-11-10T14:00:00Z2026-11-10T14:00:00Z https://www.onclive.com/view/how-relacorilant-works-and-explaining-biomarker-directed-therapy2026-11-10T13:05:00Z2026-11-10T13:05:00Z https://www.onclive.com/view/pd-l1-combined-positive-score-in-triple-negative-breast-cancer2026-11-10T13:05:00Z2026-11-10T13:05:00Z https://www.onclive.com/view/pd-l1-tumor-proportion-scoring-in-lung-cancer2026-11-10T13:00:00Z2026-11-10T13:00:00Z https://www.onclive.com/view/counseling-patients-on-biomarkers-and-cross-trial-comparisons2026-11-10T13:00:00Z2026-11-10T13:00:00Z https://www.onclive.com/view/understanding-prame-and-hla-typing-for-targeted-cellular-therapies2026-11-10T12:05:00.000Z2026-11-10T12:05:00Z https://www.onclive.com/view/addressing-unmet-needs-after-progression-on-frontline-immunotherapy2026-11-10T12:00:00.000Z2026-11-10T12:00:00Z https://www.onclive.com/view/dr-backes-on-behold-1-data-with-mocertatug-rezetecan-in-platinum-resistant-ovarian-cancer2026-11-09T22:10:00Z2026-11-09T22:10:00Z https://www.onclive.com/view/dr-patel-on-how-zidesamtinib-data-from-arros-1-compare-with-taletrectinib-data-from-trust-i-trust-ii-in-ros1-positive-nsclc2026-11-09T21:42:23.343Z2026-11-09T21:42:23.343Z https://www.onclive.com/view/melflufen-gains-eu-expansion-in-third-line-lenalidomide-refractory-multiple-myeloma2026-11-09T21:32:50.369Z2026-11-09T21:32:50.369Z https://www.onclive.com/view/nogapendekin-alfa-inbakicept-plus-bcg-meets-primary-end-point-in-bcg-naive-nmibc2026-11-09T21:15:00Z2026-11-09T21:15:00Z https://www.onclive.com/view/gedatolisib-snda-accepted-by-fda-for-pik3ca-mutated-hr-her2-advanced-breast-cancer2026-11-09T20:41:26.911Z2026-11-09T20:41:26.911Z https://www.onclive.com/view/fda-flashback-hematologic-cancer-decisions-and-news-from-october-20262026-11-09T18:01:31.507Z2026-11-09T18:01:31.507Z https://www.onclive.com/view/dr-negrao-on-olomorasib-plus-chemoimmunotherapy-in-kras-g12c-mutant-nsclc2026-11-09T16:37:56.714Z2026-11-09T16:37:56.714Z https://www.onclive.com/view/breast-cancer-s-fastest-moving-questions-which-expert-recommendations-have-held-up-2026-11-09T15:00:00Z2026-11-09T15:00:00Z https://www.onclive.com/view/bcma-directed-bispecifics-and-adcs-broaden-treatment-sequencing-options-in-r-r-myeloma2026-11-09T14:00:00Z2026-11-09T14:00:00Z https://www.onclive.com/view/azur-1-neoadjuvant-dostarlimab-for-organ-preservation-in-rectal-cancer2026-11-09T13:15:00Z2026-11-09T13:15:00Z https://www.onclive.com/view/amplify-7p-lessons-for-mutant-kras-vaccines-in-pancreatic-cancer2026-11-09T13:10:00Z2026-11-09T13:10:00Z https://www.onclive.com/view/rasolute-302-subgroup-insights-for-daraxonrasib-in-pancreatic-cancer2026-11-09T13:05:00Z2026-11-09T13:05:00Z https://www.onclive.com/view/rezilient3-zipalertinib-data-and-the-negative-furvent-readout2026-11-09T13:05:00Z2026-11-09T13:05:00Z https://www.onclive.com/view/uv1-vaccine-data-keep-htert-in-focus-as-an-immunotherapy-target-in-recurrent-ovarian-cancer2026-11-09T13:00:00Z2026-11-09T13:00:00Z https://www.onclive.com/view/herizon-gea-01-zanidatamab-data-in-her2-positive-gastroesophageal-cancer2026-11-09T13:00:00Z2026-11-09T13:00:00Z https://www.onclive.com/view/comparing-papillon-and-wu-kong28-in-first-line-selection2026-11-09T13:00:00Z2026-11-09T13:00:00Z https://www.onclive.com/view/optimizing-induction-chemoimmunotherapy-and-supportive-care-in-es-sclc2026-11-09T12:05:00.000Z2026-11-09T12:05:00Z https://www.onclive.com/view/treatment-goals-and-evolving-patient-conversations-in-small-cell-lung-cancer2026-11-09T12:00:00.000Z2026-11-09T12:00:00Z https://www.onclive.com/view/cesalatamig-monotherapy-shows-dose-dependent-activity-in-pd--l-1-inhibitor-experienced-nsclc2026-11-08T19:33:08.771Z2026-11-08T19:33:08.771Z https://www.onclive.com/view/dr-banks-on-the-feasibility-of-lifileucel-in-select-metastatic-sarcomas2026-11-08T18:32:52.351Z2026-11-08T18:32:52.351Z https://www.onclive.com/view/dr-moser-on-outcomes-for-wtx-124-pembrolizumab-in-advanced-immune-sensitive-solid-tumors2026-11-08T18:17:10.209Z2026-11-08T18:17:10.209Z https://www.onclive.com/view/jnj-87189401-plus-pasritamig-drives-deep-psa-responses-with-favorable-safety-in-pretreated-mcrpc2026-11-08T16:17:45.234Z2026-11-08T16:17:45.234Z https://www.onclive.com/view/invikafusp-alfa-plus-sacituzumab-govitecan-elicits-responses-in-tnbc-and-hr-her2-breast-cancer2026-11-08T15:53:02.797Z2026-11-08T15:53:02.797Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-11-12026-11-08T13:00:00Z2026-11-08T13:00:00Z https://www.onclive.com/view/afami-cel-outcomes-are-tied-to-mage-a4-expression-tumor-burden-in-synovial-sarcoma2026-11-08T03:26:11.857Z2026-11-08T03:26:11.857Z https://www.onclive.com/view/stx-001-produces-durable-systemic-responses-in-pd-1-resistant-melanoma2026-11-08T01:32:32.111Z2026-11-08T01:32:32.111Z https://www.onclive.com/view/rp1-plus-nivolumab-preserves-quality-adjusted-survival-in-advanced-melanoma-after-anti-pd-1-therapy2026-11-08T01:07:58.465Z2026-11-08T01:07:58.465Z https://www.onclive.com/view/vet3-tgi-generates-responses-in-checkpoint-inhibitor-refractory-cutaneous-cancers2026-11-08T00:14:56.530Z2026-11-08T00:14:56.530Z https://www.onclive.com/view/dr-isakoff-on-data-for-invikafusp-alfa-plus-sacituzumab-govitecan-in-advanced-hr-or-triple-negative-breast-cancer2026-11-07T23:39:26.339Z2026-11-07T23:39:26.339Z https://www.onclive.com/view/dr-graham-on-data-for-jnj-87189401-plus-pasritamig-in-mcrpc2026-11-07T22:37:06.718Z2026-11-07T22:37:06.718Z https://www.onclive.com/view/canakinumab-reduces-nodule-size-high-risk-lung-precancers2026-11-07T03:26:25.182Z2026-11-07T03:26:25.182Z https://www.onclive.com/view/vgx-3100-elicits-regression-and-clearance-in-hpv-16-18-associated-cervical-hsils2026-11-07T03:16:01.305Z2026-11-07T03:16:01.305Z https://www.onclive.com/view/evx-01-plus-pembrolizumab-elicits-neoantigen-specific-t-cell-responses-in-advanced-melanoma2026-11-07T02:38:17.442Z2026-11-07T02:38:17.442Z https://www.onclive.com/view/idp-023-plus-isatuximab-elicits-responses-in-daratumumab-refractory-multiple-myeloma2026-11-07T01:42:15.903Z2026-11-07T01:42:15.903Z https://www.onclive.com/view/dr-najjar-on-data-for-the-oncolytic-virus-vet3-tgi-in-advanced-solid-tumors2026-11-07T00:54:06.611Z2026-11-07T00:54:06.611Z https://www.onclive.com/view/dr-lee-on-polatuzumab-vedotin-glofitamab-and-cd19-car-t-cell-therapy-in-pediatric-refractory-burkitt-lymphoma2026-11-06T22:16:57.920Z2026-11-06T22:16:57.920Z https://www.onclive.com/view/psma-radioligand-therapy-spans-metastatic-prostate-cancer-as-next-generation-theranostics-emerge2026-11-06T22:15:00Z2026-11-06T22:15:00Z https://www.onclive.com/view/updated-capitello-281-data-support-os-advantage-with-capivasertib-in-pten-deficient-mhspc2026-11-06T21:32:26.492Z2026-11-06T21:32:26.492Z https://www.onclive.com/view/enfortumab-vedotin-plus-pembrolizumab-expands-bladder-preservation-in-mibc2026-11-06T21:28:15.723Z2026-11-06T21:28:15.723Z https://www.onclive.com/view/dr-merrill-on-selecting-patients-for-bcg-plus-durvalumab-in-high-risk-nmibc2026-11-06T19:30:00Z2026-11-06T19:30:00Z https://www.onclive.com/view/dr-garmezy-on-personalizing-treatment-intensification-in-mhspc2026-11-06T19:00:00Z2026-11-06T19:00:00Z https://www.onclive.com/view/patient-priorities-and-practice-realities-guide-treatment-selection-in-bcg-unresponsive-nmibc2026-11-06T18:30:00Z2026-11-06T18:30:00Z https://www.onclive.com/view/bcg-monotherapy-remains-the-preferred-first-move-in-bcg-naive-high-risk-nmibc2026-11-06T16:32:42.782Z2026-11-06T16:32:42.782Z https://www.onclive.com/view/zanidatamab-cldn18-2-adcs-ivonescimab-kras-inhibitor-data-key-gi-findings-esmo-20262026-11-06T15:00:00Z2026-11-06T15:00:00Z https://www.onclive.com/view/her2-mutant-nsclc-tissue-adequacy-and-repeat-biopsy2026-11-06T14:40:00Z2026-11-06T14:40:00Z https://www.onclive.com/view/her2-mutant-nsclc-molecular-testing-and-biomarker-identification2026-11-06T14:35:00Z2026-11-06T14:35:00Z https://www.onclive.com/view/adjuvant-intismeran-autogene-plus-pembrolizumab-data-headline-key-melanoma-findings-esmo-20262026-11-06T14:00:07.537Z2026-11-06T14:00:07.537Z https://www.onclive.com/view/onclive-weekly-news-quiz-11-6-2026-did-you-miss-crucial-hematologic-lung-and-desmoid-tumor-updates2026-11-06T14:00:00Z2026-11-06T14:00:00Z https://www.onclive.com/view/early-car-t-cell-referral-in-relapsed-refractory-cll2026-11-06T13:05:00Z2026-11-06T13:05:00Z https://www.onclive.com/view/patient-and-disease-factors-guide-first-line-selection2026-11-06T13:05:00Z2026-11-06T13:05:00Z https://www.onclive.com/view/litespark-012-xmab819-and-pe-pe-data-headline-key-kidney-cancer-findings-from-esmo-20262026-11-06T13:00:00Z2026-11-06T13:00:00Z https://www.onclive.com/view/resistance-mutations-and-treatment-selection-in-cll2026-11-06T13:00:00Z2026-11-06T13:00:00Z https://www.onclive.com/view/immunotherapy-reshapes-first-line-recurrent-head-and-neck-cancer2026-11-06T13:00:00Z2026-11-06T13:00:00Z https://www.onclive.com/view/bcg-optimization-becomes-a-priority-as-durvalumab-gains-a-role-in-high-risk-nmibc2026-11-06T02:30:00Z2026-11-06T02:30:00Z https://www.onclive.com/view/dr-skoulidis-on-divarasib-vs-sotorasib-or-adagrasib-in-kras-g12c-mutated-nsclc2026-11-06T01:20:00Z2026-11-06T01:20:00Z https://www.onclive.com/view/fda-approves-amivantamab-and-hyaluronidase-for-metastatic-hnscc2026-11-05T23:11:03.009Z2026-11-05T23:11:03.009Z https://www.onclive.com/view/dr-cai-on-the-rationale-for-evaluating-rocbrutinib-plus-r-chop-in-non-gcb-dlbcl-and-mcl2026-11-05T22:30:29.151Z2026-11-05T22:30:29.151Z https://www.onclive.com/view/trofuse-005-keynote-c93-and-adc-data-headline-key-gynecologic-cancer-findings-from-esmo-20262026-11-05T16:39:59.189Z2026-11-05T16:39:59.189Z https://www.onclive.com/view/palliative-and-supportive-care-time-for-recognition-of-critical-relevance2026-11-05T15:25:00Z2026-11-05T15:25:00Z https://www.onclive.com/view/dr-westin-on-development-strategies-for-b7-h4-directed-adcs-in-gynecologic-cancers2026-11-05T14:51:30.291Z2026-11-05T14:51:30.291Z https://www.onclive.com/view/psma-reach-reports-13-1-month-median-os-with-lutetium-lu-177-vipivotide-tetraxetan-in-mcrpc2026-11-05T13:00:00Z2026-11-05T13:00:00Z https://www.onclive.com/view/streamlining-car-t-cell-referral-in-dlbcl2026-11-05T12:05:00.000Z2026-11-05T12:05:00Z https://www.onclive.com/view/car-t-cell-eligibility-and-referral-in-dlbcl2026-11-05T12:00:00.000Z2026-11-05T12:00:00Z https://www.onclive.com/view/dll3-targeted-therapy-and-kras-inhibition-lead-lung-cancer-data-highlights-from-esmo-20262026-11-05T00:45:00Z2026-11-05T00:45:00Z https://www.onclive.com/view/dr-garrido-laguna-on-the-efficacy-and-safety-of-qtx3034-based-combinations-in-kras-g12d-mutated-crc2026-11-04T21:24:03.551Z2026-11-04T21:24:03.551Z